BIMINI Biotech has received a MIT feasibility grant (€20.000) for the MCL-TX project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry out a feasibility project to map the technical and economic risks of a proposed innovation project.
BIMINI’s technology has shown strong in vitro and in vivo potential in hematological cancers including diffuse large B-cell lymphoma and anaplastic large cell lymphoma. There are also strong indications that BIMINI’s compounds are effective in mantle cell lymphoma, a difficult to treat cancer with a strong unmet medical need. The MCL-TX project is aimed to investigate the technical and economic feasibility of our lead compound BM-011 in mantle cell lymphoma, with the eventual aim to provide novel therapeutics for this disease.
The ONCO-ID project is supported by the Province of Zuid-Holland.